Aquestive Therapeutics Inc (AQST)
4.595
+0.08
(+1.88%)
USD |
NASDAQ |
Nov 22, 10:17
Aquestive Therapeutics Gross Profit Margin (Quarterly): 67.24% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 67.24% |
June 30, 2024 | 77.48% |
March 31, 2024 | 63.59% |
December 31, 2023 | 64.57% |
September 30, 2023 | 63.10% |
June 30, 2023 | 50.03% |
March 31, 2023 | 57.45% |
December 31, 2022 | 50.34% |
September 30, 2022 | 59.65% |
June 30, 2022 | 60.48% |
March 31, 2022 | 65.66% |
December 31, 2021 | 69.62% |
September 30, 2021 | 66.88% |
June 30, 2021 | 70.90% |
March 31, 2021 | 75.21% |
December 31, 2020 | 61.00% |
Date | Value |
---|---|
September 30, 2020 | 63.95% |
June 30, 2020 | 83.67% |
March 31, 2020 | 58.25% |
December 31, 2019 | 58.63% |
September 30, 2019 | 62.61% |
June 30, 2019 | 51.30% |
March 31, 2019 | 72.27% |
December 31, 2018 | 71.55% |
September 30, 2018 | 57.85% |
June 30, 2018 | 64.29% |
March 31, 2018 | 75.93% |
December 31, 2017 | 53.96% |
September 30, 2017 | 82.02% |
June 30, 2017 | 53.86% |
March 31, 2017 | 74.54% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
50.03%
Minimum
Jun 2023
83.67%
Maximum
Jun 2020
64.38%
Average
63.77%
Median
Gross Profit Margin (Quarterly) Benchmarks
Rockwell Medical Inc | 22.03% |
Cormedix Inc | 94.01% |
Axogen Inc | 74.91% |
NovaBay Pharmaceuticals Inc | 65.26% |
Palatin Technologies Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Assets | -37.13% |
Profit Margin (Quarterly) | -84.99% |
Operating Margin (Quarterly) | -61.22% |
Return on Net Operating Assets | -137.1% |